| ★ | Saroglitazar Targets Bile Acid Dysregulation, Inflammation in PBC, With Raj Vuppalanchi, MD | | 55 | Estados Unidos | |
| 13 | Beyond Atherosclerosis: Coronary Calcium Scoring in Dyslipidemia, CKM Syndrome | | 2.0K | Estados Unidos | 64 |
| 19 | Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD | | 152 | Estados Unidos | 63 |
| 2 | GLP-1 Receptor Agonists Reshape CKD Treatment Sequencing, With Pranav Garimella, MD | | 151 | Estados Unidos | 69 |
| 4 | FIND-CKD Expands Finerenone Evidence Beyond Diabetic CKD, With Rajiv Agarwal, MD | | 131 | Estados Unidos | 67 |
| 7 | FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD | | 123 | Estados Unidos | 66 |
| 11 | Total Plaque Volume Indicates Patients With 0 CAC May Still be at Risk | | 120 | Estados Unidos | 65 |
| 10 | Phase 3b ENCORE: ALIS Improves MAC Lung Disease Outcomes | ATS 2026 | | 117 | Estados Unidos | 66 |
| 14 | Key Off-Label Treatment Options in Dermatology, With Matthew Zirwas, MD | | 117 | Estados Unidos | 64 |
| 20 | Lonvo-z at EAACI: Secondary Data & QoL Findings in HAE | Aleena Banerji, MD | | 91 | Estados Unidos | 63 |
| 6 | SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes | | 86 | Estados Unidos | 66 |
| 18 | GLP-1s Move Beyond Diabetes as Core Kidney-Protective Therapy | | 80 | Estados Unidos | 63 |
| 9 | Prior Authorization, Precision Medicine, and Eczema Remission, With Jason Hawkes, MD | | 69 | Estados Unidos | 66 |
| 1 | Looking Beyond ALP Response in PBC With Saroglitazar, With Raj Vuppalanchi, MD | | 68 | Estados Unidos | 76 |
| 5 | Improving Air Quality Indices for Personalized Health Warnings from Pollution Exposure | | 63 | Estados Unidos | 67 |
| 15 | SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026 | | 48 | Estados Unidos | 64 |
| 17 | Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework | | 48 | Estados Unidos | 64 |
| 12 | What Factors Should Guide Atopic Dermatitis Treatment Selection? With Walter Liszewski, MD | | 46 | Estados Unidos | 64 |
| 8 | FMD Peak Systolic Velocity May Lead to Comprehensive Clinical Guidelines | | 33 | Estados Unidos | 66 |
| 3 | Key Non-Medication Clinical Pearls for Dermatologists, With Matthew Zirwas, MD | | 21 | Estados Unidos | 67 |
| 16 | How ABCG2 Inhibition Could Change EPP Disease Management | | 17 | Estados Unidos | 64 |